Adjuvant immunotherapy improves overall survival in renal-cell carcinoma
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC
The tyrosine kinase inhibitor showed to prolong disease-free survival as compared to chemotherapy and clinically meaningful benefit with respect to CNS disease–free survival
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Breast cancer: is the future of PARP inhibitors bright?
Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
A study shows correlation between fatty acids intake and response to immunotherapy
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
Concomitant immunotherapy plus chemoradiotherapy does not improve outcomes in advanced lung cancer
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
Post-progression data confirm the benefits of novel combinations for EGFR-mutated NSCLC
Analyses of FLAURA2, MARIPOSA and MARIPOSA-2 trials provide further guidance on treatment choices for advanced lung cancer, but questions remain about optimal sequencing
Could subcutaneous administration become the standard for immunotherapy?
Two studies add further evidence of the advantages of this route for delivering immune checkpoint inhibitors for patients and healthcare sustainability